Claims
- 1. An octapeptide of the formula: ##STR3## wherein X is H, OH, CH.sub.3, or a halogen, or a pharmaceutically acceptable salt thereof.
- 2. The octapeptide of claim 1 wherein X is H.
- 3. A therapeutic composition capable of inhibiting the release of growth hormone, insulin, glucagon, or pancreatic exocrine secretion comprising a therapeutically effective amount of the compound of claim 1 together with a pharmaceutically acceptable carrier substance.
- 4. A method of treating a mammal in need of reduction of growth hormone, insulin, glucagon, or pancreatic exocrine secretion comprising administering to said mammal a therapeutically effective amount of the compound of claim 1.
- 5. The therapeutic composition of claim 3 wherein said composition is in the form of a pill, tablet, or capsule for oral administration to a human patient in need of said compound.
- 6. The therapeutic composition of claim 3 wherein said composition is in the form of a liquid for oral administration to a human patient in need of said compound.
- 7. The therapeutic composition of claim 5, said composition being coated with a substance capable of protecting said composition from the gastric acid in the stomach of said human patient for a period of time sufficient to allow said composition to pass undisintegrated into the small intestine of said human patient.
- 8. The therapeutic composition of claim 3, said composition being in the form of a cream, gel, spray, or ointment for application to the skin of a human patient in need of said compound.
- 9. The therapeutic composition of claim 3, said composition being in the form of a liquid capable of being administered nasally as drops or spray to a human patient in need of said compound.
- 10. The therapeutic composition of claim 3, said composition being in the form of a liquid for intravenous, subcutaneous, parenteral, or intraperitioneal administration to a human patient in need of said compound.
- 11. The therapeutic composition of claim 3, said composition being in the form of a biodegradable sustained release composititon for intramuscular administration to a human patient in need of said compound.
BACKGROUND OF THE INVENTION
This application is a continuation of co-pending application Ser. No. 209,883 filed on June 22, 1988, which is a continuation in part of Coy et al. U.S. Ser. No. 070,400, filed July 7, 1987, which is a continuation in part of Coy et al. U.S. Ser. No. 010,349, filed Feb. 3, 1987, which is a continuation in part of Coy et al. U.S. Ser. No. 875,266, filed June 17, 1986, which is a continuation in part of Coy et al. U.S. Ser. No. 775,488, filed Sept. 12, 1985.
US Referenced Citations (6)
Foreign Referenced Citations (4)
Number |
Date |
Country |
0029579 |
Jun 1981 |
EPX |
0203031 |
Nov 1986 |
EPX |
WO861516 |
Sep 1984 |
WOX |
2095261 |
Sep 1982 |
GBX |
Non-Patent Literature Citations (11)
Entry |
Veber et al., Life Sciences, 34:1371-1378 (1984). |
Torres-Aleman, Chemical Abstracts 102:160733u (1985). |
Schally et al., Proc. Natl. Acad. Sci. USA, 84:7275-7279 (1987). |
Siegel et al., Cancer Research, 48:4651-4655 (1988). |
Cai, "Synthesis and Evaluation of Activities of Octapeptide Analogs of Somatostatin," Nature, 292:55 (1981). |
Lamberts et al., "Potential Role of Somatostatin Analogues in the Treatment of Cancer," European J. of Clin. Invest., 17:281-287 (1987). |
Setyono-Han et al., "Direct Inhibitory Effects of Somatostatin (Analogues) on the Growth of Human Breast Cancer Cells," Cancer Research 47:1566 (1987). |
Moreau et al., "Therapeutic Advances and Perspectives," Life Sciences, 84:7275-7279 (1987). |
Reubi et al., "Somatostatin Receptors in Human Endocrine Tumors," Cancer Research, 47:551-558 (1987). |
Murphy et al., Chem. Abstracts 104:28911x (1986). |
Cai et al (1985), Proc. 9th Ann. Peptide Symposium Abstr. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
209883 |
Jun 1988 |
|
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
70400 |
Jul 1987 |
|
Parent |
10349 |
Feb 1987 |
|
Parent |
875266 |
Jun 1986 |
|
Parent |
775488 |
Sep 1985 |
|